# A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.

> **NCT07660172** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (estimated)

## Conditions studied

- Primary Immune Thrombocytopenia (ITP)

## Interventions

- **BIOLOGICAL:** Ianalumab
- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT07660172
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-02-08
- **Primary completion:** 2033-04-22
- **Final completion:** 2033-04-22
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660172, "A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.". Retrieved via MORVS 2026-10-30 from https://api.morvs.ai/clinical/NCT07660172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*